

Fernanda L Moreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1292478/publications.pdf>

Version: 2024-02-01

22
papers

157
citations

1162367

8
h-index

1199166

12
g-index

23
all docs

23
docs citations

23
times ranked

288
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. <i>Scientific Reports</i> , 2022, 12, 6454.	1.6	13
2	Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse "Berenice-78 Trypanosoma cruzi Strain Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	3
3	Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. <i>Pharmaceutical Research</i> , 2021, 38, 647-655.	1.7	2
4	Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112838.	1.4	4
5	Nonrelevant Pharmacokinetic Drug-Drug Interaction Between Furosemide and Pindolol Enantiomers in Hypertensive Parturient Women. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1527-1529.	1.0	0
6	A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1655-1661.	1.0	4
7	Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. <i>Pharmaceutical Research</i> , 2020, 37, 131.	1.7	2
8	A background subtraction approach for determination of endogenous cortisol and 6 β -hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1144, 122074.	1.2	3
9	Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1145, 122094.	1.2	4
10	A Review of Analytical Methods for the Determination of Tibolone: Pharmacokinetics and Pharmaceutical Formulations Analysis and Application in Doping Control. <i>Current Pharmaceutical Analysis</i> , 2020, 17, 31-39.	0.3	0
11	Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. <i>Critical Reviews in Analytical Chemistry</i> , 2018, 48, 317-329.	1.8	14
12	Leishmanicidal Effects of Piperlongumine (Piplartine) and Its Putative Metabolites. <i>Planta Medica</i> , 2018, 84, 1141-1148.	0.7	12
13	Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2415-2421.	1.1	6
14	In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin. <i>Planta Medica</i> , 2017, 83, 727-736.	0.7	10
15	In vitro metabolism studies of natural products are crucial in the early development of medicines. <i>Phytochemistry Reviews</i> , 2017, 16, 355-373.	3.1	4
16	Metabolic profile and safety of piperlongumine. <i>Scientific Reports</i> , 2016, 6, 33646.	1.6	24
17	In vitro enantioselective human liver microsomal metabolism and prediction of in vivo pharmacokinetic parameters of tetrabenazine by DLLME-CE. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 128, 528-537.	1.4	7
18	Formation of a Predominant Metabolite of Hydroxydihydrocarvone Evaluated by a Biomimetic Oxidative Model and in Rat Liver Microsomes. <i>Planta Medica Letters</i> , 2015, 2, e61-e64.	0.2	0

#	ARTICLE	IF	CITATIONS
19	<i>In vitro</i> metabolism of the lignan (â)â€grandisin, an anticancer drug candidate, by human liver microsomes. Drug Testing and Analysis, 2015, 7, 780-786.	1.6	12
20	<i>In vitro</i> metabolism of monensin A: microbial and human liver microsomes models. Xenobiotica, 2014, 44, 326-335.	0.5	12
21	A non-michaelian behavior of the <i>in vitro</i> metabolism of the pentacyclic triterpene alfa and beta amyryns by employing rat liver microsomes. Journal of Pharmaceutical and Biomedical Analysis, 2013, 84, 14-19.	1.4	18
22	Evaluation of the Influence of Splitting on Content Uniformity of Captopril Tablets. Current Pharmaceutical Analysis, 2013, 9, 139-144.	0.3	1